WO2020006298A3 - Polypeptides à base de cyclotide pour le ciblage thérapeutique de récepteurs baff dans le lupus érythémateux systémique les - Google Patents

Polypeptides à base de cyclotide pour le ciblage thérapeutique de récepteurs baff dans le lupus érythémateux systémique les Download PDF

Info

Publication number
WO2020006298A3
WO2020006298A3 PCT/US2019/039605 US2019039605W WO2020006298A3 WO 2020006298 A3 WO2020006298 A3 WO 2020006298A3 US 2019039605 W US2019039605 W US 2019039605W WO 2020006298 A3 WO2020006298 A3 WO 2020006298A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclotide
sle
therapeutic targeting
based polypeptides
baff receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/039605
Other languages
English (en)
Other versions
WO2020006298A2 (fr
Inventor
Julio Camarero PALAO
Chaim JACOB
William STOHL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of WO2020006298A2 publication Critical patent/WO2020006298A2/fr
Publication of WO2020006298A3 publication Critical patent/WO2020006298A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une méthode à haut rendement pour identifier et isoler un antagoniste du récepteur BAFF candidat et des méthodes pour son utilisation in vitro et in vivo.
PCT/US2019/039605 2018-06-28 2019-06-27 Polypeptides à base de cyclotide pour le ciblage thérapeutique de récepteurs baff dans le lupus érythémateux systémique les Ceased WO2020006298A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862691564P 2018-06-28 2018-06-28
US62/691,564 2018-06-28

Publications (2)

Publication Number Publication Date
WO2020006298A2 WO2020006298A2 (fr) 2020-01-02
WO2020006298A3 true WO2020006298A3 (fr) 2020-02-06

Family

ID=68985175

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/039605 Ceased WO2020006298A2 (fr) 2018-06-28 2019-06-27 Polypeptides à base de cyclotide pour le ciblage thérapeutique de récepteurs baff dans le lupus érythémateux systémique les

Country Status (1)

Country Link
WO (1) WO2020006298A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI776067B (zh) 2018-06-29 2022-09-01 美商維托平面玻璃有限責任公司 可燒除保護性塗層
WO2021163989A1 (fr) * 2020-02-21 2021-08-26 Yinnuolai Biotech Ltd. Anticorps anti-récepteur baff et leurs utilisations
CN115120704B (zh) * 2022-07-25 2023-03-24 山东中医药大学 一种通过降低神经细胞氧化损伤来治疗抑郁症的药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070689A1 (en) * 2001-08-03 2005-03-31 Genentech, Inc. Taci and br3 polypeptides and uses thereof
US20170239327A9 (en) * 2011-12-22 2017-08-24 Medizinische Universitat Wien Cyclotides as immunosuppressive agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070689A1 (en) * 2001-08-03 2005-03-31 Genentech, Inc. Taci and br3 polypeptides and uses thereof
US20170239327A9 (en) * 2011-12-22 2017-08-24 Medizinische Universitat Wien Cyclotides as immunosuppressive agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PELLETIER ET AL.: "Comparison of Soluble Decoy IgG Fusion Proteins of BAFF-R and BCMA as Antagonists for BAFF", J. BIOL. CHEM., vol. 278, no. 35, 29 August 2003 (2003-08-29), pages 33127 - 33133, XP002321479, DOI: 10.1074/jbc.M305754200 *

Also Published As

Publication number Publication date
WO2020006298A2 (fr) 2020-01-02

Similar Documents

Publication Publication Date Title
IL288046A (en) Improved culture method using integrin agonist
SG11202009017WA (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
WO2020006298A3 (fr) Polypeptides à base de cyclotide pour le ciblage thérapeutique de récepteurs baff dans le lupus érythémateux systémique les
SG11202106787SA (en) Receptors providing targeted costimulation for adoptive cell therapy
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
CO6781536A2 (es) Agonistas de fgfr1 y sus métodos de uso
WO2011154139A3 (fr) Marqueurs d'expression génique pour la prédiction d'une réponse à un traitement par un médicament anticorps monoclonal inhibant le récepteur de l'interleukine-6
CA3289997A1 (en) Monoclonal Antibodies Specific for Fibroblast Growth Factor Receptor 4 (FGFR4) and Methods of Their Use
ZA202100125B (en) Novel fusion protein specific for cd137 and pd-l1
SG11202012529VA (en) Means and methods for increased protein expression by use of transcription factors
EP4003161A4 (fr) Sonde optoacoustique
EP4081819A4 (fr) Appareil pour la mesure de minerai dans des bancs de minerai de mine
EP4035160A4 (fr) Procédés d'analyse pour imagerie de tissu multiplex comprenant des données d'imagerie par cytométrie de masse
SG11202101789SA (en) Method for generating cells into which an exogenous antigen receptor is introduced
EP3831845A4 (fr) Récepteur de lymphocytes t pour identifier un antigène afp
GB2603330B (en) Heterocyclic THR-B receptor agonist compound and preparation method and use therefor
EP3842550A4 (fr) Procédé d'analyse d'un gène de paire de sous-unités fonctionnelles d'un récepteur des lymphocytes t et d'un récepteur des lymphocytes b
EP3966421A4 (fr) Appareil de tête de cimentation
IL290221A (en) T-cell receptors and methods for their use
FR3083690B1 (fr) Procede de determination de l'etat de stress d'un individu
IL281767A (en) CD137-directed antibodies and methods of using them
EP3617728B8 (fr) Système de sonde rmn et procédé d'utilisation d'un système de sonde rmn
EP4077369A4 (fr) Procédés pour identifier des modulateurs de récepteurs couplés à la protéine g
ZA202110199B (en) Screening method of markers for prediction of preterm delivery, preterm delivery test kit and use thereof
HK40080649A (en) Methods of using il-33 antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19826548

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19826548

Country of ref document: EP

Kind code of ref document: A2